Compare ELDN & XFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELDN | XFLT |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | 33 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.1M | 256.8M |
| IPO Year | 2014 | N/A |
| Metric | ELDN | XFLT |
|---|---|---|
| Price | $3.10 | $17.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 323.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.17% |
| EPS Growth | ★ 30.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $3.02 |
| 52 Week High | $4.60 | $17.77 |
| Indicator | ELDN | XFLT |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 90.13 |
| Support Level | $2.45 | $4.93 |
| Resistance Level | $3.17 | N/A |
| Average True Range (ATR) | 0.20 | 0.44 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 70.00 | 92.38 |
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.